Posts Tagged ‘innovation’

The Intersection of Drug Prices, Insurance, and Obesity

January 31, 2023 — There’s an ugly accident at the intersection of U.S. drug prices, health insurance, and obesity. In a report yesterday, NPR reporter Allison Aubrey described how people living with obesity, after finding at long last that they have an option to get their medical condition under control, learn that they’re at the mercy of excessive drug […]

Competing Lies About Obesity Fall Apart

January 16, 2023 — We are living in a pivotal moment for the public understanding of a common and complex chronic disease. It is a moment when two competing, but very different, lies about obesity are falling apart. Simply Bad Choices On one hand, the big lie about obesity for decades has been that it is a simple matter […]

Unsettling Arrival: A Pediatric Obesity Guideline

January 9, 2023 — This is indisputably good news. But the arrival of the first ever pediatric obesity treatment guideline is also most certainly unsettling. It’s good news because the American Academy of Pediatrics (AAP) is finally saying that it’s not OK to sit back and watch kids for whom obesity is causing great harm to their health and […]

Can AI Explain Obesity Better Than Humans?

December 18, 2022 — More than a few writers have been worrying lately about a new artificial intelligence app, ChatGPT. In the Guardian, Alex Hern supposed that it will put professors and journalists out of their jobs. So we wondered. Could this implementation of AI demonstrate an understanding of obesity? The obvious answer was to give it a try. […]

The Most Read Posts on ConscienHealth in 2022

December 16, 2022 — We’re zooming toward the end of 2022, so it’s hard to resist looking back to see which of the posts on ConscienHealth you read the most. We are grateful for the smart and diverse people who take the time to read what we post here. Seeing what captures your attention teaches us a thing or […]

Amgen Bringing More Competition into Obesity

December 5, 2022 — Move over, Novo Nordisk and Eli Lilly. Amgen wants a piece of the action in obesity treatment. With some obvious pride of accomplishment, Amgen unveiled results from a phase 1 study of its dual action conjugate on Saturday. This new experimental drug, AMG 133, is a molecule that combines peptides to activate GLP-1 receptors (as […]

Can We Afford Optimism About Treating Obesity?

November 25, 2022 — “Can’t never could.” This old bit of Southern American wisdom aptly describes one of the startling reactions to impressive progress in obesity treatment – “we can’t do this. It will cost too much.” This reaction has been part of the landscape of obesity care for some time, so it should not be startling. But when […]

Hype Falls to Reality in Dull Sales of Fake Meat

November 8, 2022 — It was lovely speculation while it lasted. Ultra-processed fake meat was going to save the planet and our health. Pat Brown, the founder and former CEO of Impossible Foods, claimed he could conjure up plant-based meat that’s “vastly better” than real meat. Even McDonald’s took the bait and began testing the McPlant™ burger. But unsurprisingly […]

A Strained Supply of Obesity and Diabetes Meds

November 7, 2022 — There’s a clue in the strained supply of new obesity and diabetes meds that most everyone is missing. For more than a year now, Novo Nordisk has been unable to produce and distribute an adequate supply of semaglutide in the form of Wegovy for the treatment of obesity. This has knock-on effects. So supply of […]

OW2022: Clearing a Path to Better Obesity Care

November 2, 2022 — Opening ObesityWeek with a quick succession of pithy talks to set the agenda for the week seems to be a good way of getting getting the attention of the diverse audience focused on obesity. Last night, it worked. A series of talks served to focus the group on the theme for OW2022 that President Dan […]